Month: February 2023

HAMILTON, Bermuda, Feb. 14, 2023 (GLOBE NEWSWIRE) — Textainer Group Holdings Limited (NYSE: TGH; JSE: TXT) (“Textainer”, “the Company”, “we” and “our”), one of the world’s largest lessors of intermodal containers, today reported financial results for the fourth-quarter and full-year ended December 31, 2022. Key Financial Information (in thousands except for per share and TEU amounts) and Business Highlights:    QTD     Full-Year      Q4 2022     Q3 2022     Q4 2021     2022     2021  Total lease rental income   $ 202,912     $ 205,152     $ 198,222     $ 810,014     $ 750,730  Gain on sale of owned fleet containers, net   $ 15,033     $ 22,788     $ 16,007     $ 76,947     $ 67,229  Income from operations   $ 111,544     $ 123,292     $ 113,986     $ 472,399     $ 430,131  Net income attributable to common shareholders   $ 61,854     $ 76,400     $ 72,885     $ 289,549     $ 273,459  Net...

CHICAGO, Feb. 14, 2023 (GLOBE NEWSWIRE) — GCM Grosvenor (Nasdaq: GCMG), a leading global alternative asset management solutions provider, today reported results for the fourth quarter and full year ended December 31, 2022. “Against a tough backdrop we are pleased to have added value for clients and shareholders.” said Michael Sacks, Chairman and Chief Executive Officer of GCM Grosvenor. “Our private markets strategies continue to grow at solid rates and the opportunity set for our platform remains strong.” Assets Under ManagementFee-Paying Assets Under Management (“FPAUM”) remained relatively flat from December 31, 2021 (the “prior year”) at $58.9 billion as of December 31, 2022Private Markets FPAUM increased 11% from the prior year to $36.9 billion as of December 31, 2022 Absolute Return Strategies FPAUM decreased 14% from...

Fourth Quarter 2022 HighlightsSales of $489.4 million, an increase of 13% over the prior year, was a fourth quarter record Robust sales growth in all three Segments; Distribution up 27%, Water Systems up 9%, and Fueling Systems up 8% Operating income was a fourth quarter record at $56.2 million, an increase of 19% over the prior year GAAP fully diluted earnings per share (EPS) was $0.84, a decrease of $0.01 to prior yearFull Year 2022 HighlightsFull Year record sales of $2.0 billion, an increase of 23% over the prior year Strong sales growth in all three Segments; Distribution up 34%, Water Systems up 20%, and Fueling Systems up 16% Operating income for 2022 was a record at $257.2 million, an increase of 36% over the prior year GAAP fully diluted EPS was a record at $3.97, an increase of 22% over the prior yearFORT WAYNE, Ind.,...

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION INTHE UNITED STATES OR TO U.S. NEWS AGENCIES HONG KONG, Feb. 14, 2023 (GLOBE NEWSWIRE) — Century Global Commodities Corporation (“Century” or the “Company”) (TSX: CNT) is pleased to announce that it has filed its condensed consolidated interim financial statements for the third fiscal quarter ended December 31, 2022 and the related management discussion and analysis (“MD&A”). Copies of these documents are available under Century’s SEDAR profile at www.sedar.com and will also be posted on Century’s website at www.centuryglobal.ca. As of December 31, 2022, the Company had strong net working capital* of $9.4 million, consisting of cash, bank deposits and marketable securities totaling $6.5 million, together with accounts receivables and other current assets of $5.6 million, less accounts...

Sustained Revenue Growth Driven by 27% Organic Growth Key financial highlights(All comparisons are relative to the three-month period ended December 31, 2021, unless otherwise stated)Revenue growth of 52.0% reaching $63.9 M from $42.0 M; Organic revenue growth of 26.8%, compared to 16.2%, with recurring revenues by nature of 90%; Adjusted EBITDA1 reached $6.5 M, compared to $3.8 M; Net earnings amounted to $0.6 M, compared to $0.8 M; Adjusted net earnings1 of $2.7 M, compared to $2.0 M; and Consolidated backlog of $206.2 M as at the end of the second quarter of fiscal year 2023, up to 63.4%.All amounts in Canadian dollars unless otherwise stated. QUEBEC CITY, Feb. 14, 2023 (GLOBE NEWSWIRE) — (TSX: HEO) – H2O Innovation Inc. (“H2O Innovation” or the “Corporation”) announces its financial results for the second quarter of its...

Continued Growth in E-mobility, Renewable Energy and Medical Inventory Related Charges, Impairment of Long-Lived Assets and Restructuring Charges Impact Operating Results MARLBOROUGH, Mass., Feb. 14, 2023 (GLOBE NEWSWIRE) — IPG Photonics Corporation (Nasdaq: IPGP) today reported financial results for the fourth quarter ended December 31, 2022.    Three Months Ended December 31,       Twelve Months Ended December 31,      (In millions, except per share data and percentages)   2022   2021   Change   2022   2021   ChangeRevenue   $ 333.5     $ 364.5     (8)%   $ 1,429.5     $ 1,460.9     (2 )%Gross margin     18.2  %     45.5  %         38.9  %     47.7  %      Operating (loss) income   $ (88.5 )   $ 84.8     NM   $ 169.5     $ 367.9     (54 )%Operating margin     (26.5 )%     23.3  %         11.9  %     25.2  %      Net...

– Second quarter total revenue and government support income increased over 100% year-over-year – – Government support income increased 52% for the quarter ended December 31, 2022 compared to the prior corresponding period, mainly due to qualifying expenditures for completion of Milestone 7 – – Successful completion of Milestone 7, a key phase of its biosensor platform development – – Cash and cash equivalents at quarter-end totaled $2.9 million – NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (“Intelligent Bio Solutions” or the “Company”) (Nasdaq: INBS), a life sciences company developing and delivering intelligent, non-invasive, real-time testing solutions, today announced its financial results for its fiscal second quarter ended December 31, 2022, and...

Pre-launch commercial activities underway as Company advances toward U.S. Food and Drug Administration (FDA) Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023 for ONS-5010 / LYTENAVA™ (bevacizumab-vikg), an investigational ophthalmic formulation for the treatment of wet age-related macular degeneration (wet AMD) Cash runway through the anticipated FDA approval of ONS-5010 in the third calendar quarter of 2023 and into the fourth calendar quarter of 2023ISELIN, N.J., Feb. 14, 2023 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced recent corporate highlights and financial results for its fiscal first quarter ended December 31,...